39
Participants
Start Date
August 1, 2017
Primary Completion Date
July 20, 2021
Study Completion Date
April 24, 2024
TAK-228
TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
University of Michigan, Ann Arbor
University of Minnesota, Minneapolis
University of Chicago Medical Center, Chicago
University of Colorado Cancer Center, Aurora
University of California, San Diego Moores Cancer Center, La Jolla
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Collaborators (1)
Calithera Biosciences, Inc
INDUSTRY
Bradley A. McGregor, MD
OTHER